Mineralys Therapeutics Appoints New Directors, Updates Executive Contracts
Ticker: MLYS · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1933414
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Mineralys adds 2 directors, inks new CEO/CMO deals.
AI Summary
Mineralys Therapeutics, Inc. announced on June 13, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. David R. Walt and Ms. Sarah E. Emond, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Amy T. Peterson, and Chief Medical Officer, Dr. Jonathan F. Leff, effective June 13, 2024.
Why It Matters
The election of new directors and updated executive compensation can signal strategic shifts or confidence in leadership, potentially impacting investor sentiment and future company direction.
Risk Assessment
Risk Level: low — This filing primarily concerns board appointments and executive compensation, which are routine corporate governance matters and do not inherently present significant new risks.
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Registrant
- Dr. David R. Walt (person) — Newly Elected Director
- Ms. Sarah E. Emond (person) — Newly Elected Director
- Dr. Amy T. Peterson (person) — Chief Executive Officer
- Dr. Jonathan F. Leff (person) — Chief Medical Officer
- June 13, 2024 (date) — Effective Date of Changes
FAQ
Who were the new directors elected to Mineralys Therapeutics' Board?
Dr. David R. Walt and Ms. Sarah E. Emond were elected as new directors to the Board of Directors of Mineralys Therapeutics, Inc.
When were the changes to the Board of Directors and executive agreements effective?
The changes reported in this Form 8-K were effective as of June 13, 2024.
What positions do Dr. Amy T. Peterson and Dr. Jonathan F. Leff hold at Mineralys Therapeutics?
Dr. Amy T. Peterson is the Chief Executive Officer and Dr. Jonathan F. Leff is the Chief Medical Officer of Mineralys Therapeutics, Inc.
What type of agreements were entered into with the CEO and CMO?
Mineralys Therapeutics, Inc. entered into new employment agreements with its Chief Executive Officer, Dr. Amy T. Peterson, and Chief Medical Officer, Dr. Jonathan F. Leff.
In which state is Mineralys Therapeutics, Inc. incorporated?
Mineralys Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 897 words · 4 min read · ~3 pages · Grade level 9.8 · Accepted 2024-06-14 08:06:33
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share MLYS The Nasdaq Stock Marke
Filing Documents
- mlys-20240613.htm (8-K) — 27KB
- 0001933414-24-000028.txt ( ) — 156KB
- mlys-20240613.xsd (EX-101.SCH) — 2KB
- mlys-20240613_lab.xml (EX-101.LAB) — 23KB
- mlys-20240613_pre.xml (EX-101.PRE) — 13KB
- mlys-20240613_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 14, 2024 MINERALYS THERAPEUTICS, INC. By: /s/ Adam Levy Name: Adam Levy Title: Chief Financial Officer and Secretary